BRIEF-Abbvie says investigational IL-23 inhibitor Risankizumab receives Orphan Drug Designation from U.S. FDA

* Abbvie receives Orphan Drug Designation for
investigational IL-23 inhibitor Risankizumab from the U.S. Food
and Drug Administration for the treatment of pediatric patients
with Crohn’s…

The post BRIEF-Abbvie says investigational IL-23 inhibitor Risankizumab receives Orphan Drug Designation from U.S. FDA appeared first on NASDAQ.